Case of Secondary Amyloidosis in a Patient with Ankylosing Spondylitis Refractory to TNF-alpha Inhibitors / 대한내과학회지
Korean Journal of Medicine
;
: 514-519, 2014.
Artigo
em Coreano
| WPRIM
| ID: wpr-176482
ABSTRACT
Secondary amyloidosis occurs in patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). The major therapeutic approach to secondary amyloidosis involves controlling the underlying inflammatory disease. Tumor necrosis factor-alpha (TNF-alpha) inhibitors have revolutionized the treatment of rheumatic diseases; in many cases dramatic clinical improvement of secondary amyloidosis due to AS has been observed in response to treatment with these agents. However, the development of secondary amyloidosis associated with AS refractory to treatment with TNF-alpha inhibitors has been infrequently reported. Here, we described a case of a 37-year-old male patient with longstanding AS who was diagnosed with secondary amyloidosis due to high disease activity despite treatment with etanercept, adalimumab and infliximab.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Artrite Reumatoide
/
Espondilite Anquilosante
/
Doenças Reumáticas
/
Fator de Necrose Tumoral alfa
/
Adalimumab
/
Infliximab
/
Etanercepte
/
Amiloidose
Limite:
Adulto
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS